S. Kim

发表

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

R. Motzer, M. Gore, R. Motzer, 2011, The Lancet.

Isolation and Characterization of Monokaryotic Strains of Lentinula edodes Showing Higher Fruiting Rate and Better Fruiting Body Production

H. Ro, Byeong-suk Ha, S. Kim, 2015, Mycobiology.

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

R. Motzer, B. Rini, D. Quinn, 2014, Targeted Oncology.

Clinic and Home Blood Pressure Measurements are Reliable for Guiding Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Axitinib as First-Line Therapy

M. Fishman, B. Rini, M. Carducci, 2012 .

Quantitative cerebrospinal fluid cytology in patients receiving intracavitary chemotherapy

V. Russack, M. Chamberlain, S. Kim, 1993, Annals of neurology.

Pharmacokinetics of an extended-release human interferon alpha-2b formulation

A. Bonetti, S. Kim, 2004, Cancer Chemotherapy and Pharmacology.

Sustained‐release Morphine for Epidural Analgesia in Rats

A. Gruber, S Kim, S. Murdande, 1996, Anesthesiology.

Evaluation of copper-inducible fungal laccase promoter in foreign gene expression in Pichia pastoris

H. Ro, Minsa Park, Minseek Kim, 2016, Biotechnology and Bioprocess Engineering.

Differential Expression of Laccase Genes in Pleurotus ostreatus and Biochemical Characterization of Laccase Isozymes Produced in Pichia pastoris

Sinil Kim, H. Ro, Minsa Park, 2015, Mycobiology.

Nucleus-Selective Expression of Laccase Genes in the Dikaryotic Strain of Lentinula edodes

H. Ro, Y. Moon, Yelin Song, 2017, Mycobiology.

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

A. Brenner, M. Borad, Yoon-Koo Kang, 2017, Investigational New Drugs.

Liposomes as Carriers of Cancer Chemotherapy

S. Kim, 1993, Drugs.

Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes

S. Howell, S. Kim, David J. Kim, 2004, Cancer Chemotherapy and Pharmacology.

Growth Characteristics of Polyporales Mushrooms for the Mycelial Mat Formation

H. Ro, Minseek Kim, S. Kim, 2021, Mycobiology.

Current Technologies and Related Issues for Mushroom Transformation

H. Ro, Byeong-suk Ha, S. Kim, 2015, Mycobiology.

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

E. Vokes, P. Bycott, L. Rosen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

R. Motzer, M. Gore, M. Michaelson, 2013, The Lancet. Oncology.

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

K. Kelnar, Keunchil Park, A. Brenner, 2020, British Journal of Cancer.

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

B. Rini, J. Schiller, E. Cohen, 2011, Clinical Cancer Research.

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

G. Wilding, B. Rini, G. Hudes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

R. Motzer, M. Michaelson, G. Wilding, 2007, The Lancet. Oncology.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

G. Scagliotti, S. Novello, I. Bondarenko, 2014, BMC Cancer.

Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.

R. Motzer, B. Rini, Xin Huang, 2015, Clinical genitourinary cancer.

Pharmacokinetics of single-agent axitinib across multiple solid tumor types

E. Cohen, Y. Pithavala, M. Tortorici, 2014, Cancer Chemotherapy and Pharmacology.

Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)

R. Motzer, M. Michaelson, B. Redman, 2005 .

Diversity of A mating type in Lentinula edodes and mating type preference in the cultivated strains

H. Ryu, H. Ro, Y. Moon, 2018, Journal of Microbiology.

Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

R. Finn, N. Shaik, J. Glaspy, 2009 .

Structure analysis of A and B mating type loci in a representative commercial strain of Pleurotus eryngii

H. Ro, Minseek Kim, J. Ryu, 2020 .

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

N. Vogelzang, V. Lesovoy, Thomas E. Hutson, 2013, The Lancet. Oncology.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

E. Jonasch, M. Fishman, B. Melichar, 2013, The Lancet. Oncology.

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

H. Akaza, Y. Tomita, S. Naito, 2013, Japanese journal of clinical oncology.

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

D. McDermott, J. Lutzky, D. Shalinsky, 2011, Clinical Cancer Research.

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736).

B. Rini, J. Schiller, E. Cohen, 2008 .

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

T. Larson, E. Vokes, J. von Pawel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

E. Van Cutsem, D. Richel, J. Furuse, 2011, The Lancet. Oncology.

Variable Number Tandem Repeats in the Mitochondrial DNA of Lentinula edodes

H. Ryu, H. Ro, Y. Moon, 2019, Genes.

Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC).

P. Bycott, N. Vogelzang, J. Tarazi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel nuclear targeting coiled-coil protein of Helicobacter pylori showing Ca2+-independent, Mg2+-dependent DNase I activity

Yong Seok Lee, Hyung-Lyun Kang, Je Chul Lee, 2016, Journal of Microbiology.

Cancer Therapy : Clinical Multicenter , Phase II Study of Axitinib , a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1 , 2 , and 3 , in Patients with Metastatic Melanoma

D. McDermott, J. Lutzky, D. Shalinsky, 2011 .

Multivesicular Liposomes Containing 1-^-D-Arabinofuranosylcytosinefor Slow-Release Intrathecal Therapy1

M. Geyer, S. Howell, S. Kim, 1987 .

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

M. Moore, J. Spano, A. Ricart, 2012, Investigational New Drugs.

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

P. Bycott, J. Maurel, H. Wasan, 2008, The Lancet.

Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma

B. Rini, J. Cappelleri, P. Bycott, 2011, Journal of cancer survivorship.

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

H. Rugo, A. Stopeck, P. Bycott, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC)

H. Rugo, A. Stopeck, P. Bycott, 2007 .

Oncotargets and Therapy Dovepress Axitinib versus Sorafenib as a Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma: Results from a Randomized Registrational Study

Ying Cheng, D. Ye, Yiran Huang, 2022 .

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

R. Motzer, G. Wilding, B. Rini, 2013, Journal of clinical pharmacology.

Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

R. Motzer, B. Redman, G. V. Kondagunta, 2007 .

Extended-release formulation of morphine for subcutaneous administration

Sinil Kim, Joon Kim, Taehee Kim, 2004, Cancer Chemotherapy and Pharmacology.

Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.

R. Motzer, M. Michaelson, B. Rini, 2013, Clinical genitourinary cancer.

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

R. Figlin, R. Motzer, M. Michaelson, 2008 .

Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib

G. Wilding, B. Rini, P. Bycott, 2007 .

Investigation of Mating Pheromone–Pheromone Receptor Specificity in Lentinula edodes

H. Ro, Minseek Kim, Byeongsuk Ha, 2020, Genes.

Genetic incorporation of Nε-acetyllysine reveals a novel acetylation-sumoylation switch in yeast.

Hee-Sung Park, Sinil Kim, H. Ro, 2017, Biochimica et biophysica acta. General subjects.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors

R. Figlin, R. Motzer, R. Bukowski, 2007 .

Axitinib (AG-013736) in combination with FOLFOX and bevacizumab (Bev) in patients (pts) with metastatic solid tumors: A phase I study

R. Robles, M. Tortorici, B. Hee, 2008 .

DepoFoam-Mediated Drug Delivery into Cerebrospinal Fluid

S. Kim, 1994 .

Multivesicular liposomes containing bleomycin for subcutaneous administration

Sinil Kim, Romi Roy, S. Kim, 2004, Cancer Chemotherapy and Pharmacology.

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments

S. Ou, P. Bycott, E. Cohen, 2014, Cancer.

Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial

T. Larson, E. Vokes, J. Schiller, 2007 .

Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

R. Finn, J. Glaspy, S. Hurvitz, 2010 .

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone

G. Wilding, B. Rini, G. Hudes, 2008 .

Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer

K. Wilner, P. LoRusso, P. Chapman, 2007 .

Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.

E. Jonasch, M. Fishman, B. Melichar, 2012 .

Novel nuclear targeting coiled-coil protein of Helicobacter pylori showing Ca2+-independent, Mg2+-dependent DNase I activity

Yong Seok Lee, Je Chul Lee, Woo-Kon Lee, 2016, Journal of Microbiology.

Mitochondrial Effects on the Physiological Characteristics of Lentinula edodes

H. Ro, Minseek Kim, Y. Oh, 2022, Mycobiology.

LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy

K. Spindler, M. Fakih, M. Cornfeld, 2020 .

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

C. Tournigand, Z. Wainberg, J. Bendell, 2013, Clinical colorectal cancer.

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

J. Hamm, J. Infante, W. Edenfield, 2013, Cancer.

A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies

S. Howell, S. Kirmani, E. McClay, 1994, Cancer.

MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.

Keunchil Park, A. Brenner, M. Borad, 2016 .

Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors

A. Brenner, M. Borad, D. Hong, 2015 .

O-0026 Significant Relationship Between CA19-9 Kinetics and Overall Survival (OS) from a Phase 3 Trial in Advanced Pancreatic Cancer (APC).

D. Richel, H. Wasan, A. Ricart, 2012 .

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

I. Bondarenko, P. Bycott, A. Ingrosso, 2015, BMC Cancer.

4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib

G. Wilding, B. Rini, P. Bycott, 2007 .

J. Cappelleri, P. Bycott, A. Bushmakin, 2008, Acta oncologica.

A Phase II Trial of Intraperitoneal High‐Dose Carboplatin and Etoposide with Granulocyte Macrophage‐Colony Stimulating Factor Support in Patients with Ovarian Carcinoma

S. Howell, E. McClay, S. Plaxe, 1995, American journal of clinical oncology.

Activation of the Mating Pheromone Response Pathway of Lentinula edodes by Synthetic Pheromones

H. Ro, Minseek Kim, Byeongsuk Ha, 2018, Mycobiology.

Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.

E. Jonasch, M. Fishman, B. Melichar, 2013, Journal of Clinical Oncology.

A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN).

D. Heron, J. Grandis, R. Ferris, 2010 .

The Cas9-gRNA ribonucleoprotein complex-mediated editing of pyrG in Ganoderma lucidum and unexpected insertion of contaminated DNA fragments

T. Nakazawa, H. Ro, Minseek Kim, 2023, Scientific reports.

Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival

R. Motzer, M. Michaelson, B. Redman, 2007 .

TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α).

R. Figlin, R. Motzer, Xin Huang, 2010 .

Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison

Á. Benedict, C. Charbonneau, S. Négrier, 2008 .

Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

M. Chamberlain, S. Howell, E. Chatelut, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.

S. Howell, S. Kirmani, S. Kim, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes.

M. Geyer, S. Howell, S. Kim, 1990, Journal of Infectious Diseases.

R. Motzer, R. Motzer, M. Michaelson, 2010, British Journal of Cancer.

Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-{alpha})

R. Motzer, M. Michaelson, D. Cella, 2007 .

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

S. Saltzstein, S. Howell, P. Braly, 1994, Gynecologic Oncology.

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

J. Maurel, H. Wasan, J. Spano, 2009, British Journal of Cancer.

Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam.

F. Balis, S. Howell, D. Poplack, 1993, Cancer research.

Preparation of multivesicular liposomes.

S. Sela, M. Turker, S Sela, 1983, Biochimica et biophysica acta.

Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study.

M. Chamberlain, S. Howell, E. Chatelut, 1993, Archives of neurology.

Structural Analysis of the A Mating Type Locus and Development of the Mating Type Marker of Agaricus bisporus var. bisporus

H. Ro, Yeon-Jae Choi, Hui-Gang Han, 2023, Journal of fungi.

Commentary on "Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase

D. Cella, C. Szczylik, B. Escudier, 2012 .

Comparative structural analysis on the mitochondrial DNAs from various strains of Lentinula edodes

H. Ryu, H. Ro, Yeon-Jae Choi, 2022, Frontiers in Microbiology.

A slow-release methotrexate formulation for intrathecal chemotherapy

E. Chatelut, Taehee Kim, S. Kim, 2004, Cancer Chemotherapy and Pharmacology.

Variable Number Tandem Repeats in the Mitochondrial DNA of Lentinula edodes

H. Ryu, H. Ro, Y. Moon, 2019, Genes.

Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma

R. Motzer, J. Beaumont, D. Cella, 2005 .

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses

P. Bycott, E. Cohen, Y. Pithavala, 2014, Cancer Chemotherapy and Pharmacology.

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

D. McDermott, J. Lutzky, D. Shalinsky, 2011, Clinical Cancer Research.

Molecular analysis of B mating type diversity in Lentinula edodes

H. Ro, Y. Moon, Yelin Song, 2019, Scientia Horticulturae.

Diversity of A mating type in Lentinula edodes and mating type preference in the cultivated strains

H. Ryu, Sinil Kim, H. Ro, 2018, Journal of Microbiology.

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

B. Rini, J. Schiller, E. Cohen, 2011, Clinical Cancer Research.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

P. Bycott, L. Havel, E. Chmielowska, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Grandis, P. Harari, A. Argiris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN).

D. Heron, J. Grandis, R. Ferris, 2010 .

Heterokaryosis, the main obstacle in the generation of PPO1-edited Agaricus bisporus by CRISPR/Cas9 system

Y. Honda, T. Nakazawa, H. Ro, 2023, Scientia Horticulturae.

A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer

E. Vokes, P. Bycott, L. Rosen, 2006 .

Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs)

E. Heath, P. LoRusso, G. Wilding, 2008 .